

This listing of claims will replace all prior versions, and listings of claims, in the application:

Listing of Claims:

1-14. (canceled)

15. (currently amended) A composition comprising (i) a non replicative recombinant adenoviral vector wherein said non replicative recombinant adenoviral vector comprises a heterologous polynucleotide sequence encoding a polypeptide, which polynucleotide sequence is inserted into a deleted E1 region of said non replicative recombinant adenoviral vector and is under the control of a promoter ~~selected from the promoter~~ contained in the Long Terminal Repeat of Rous Sarcoma Virus, wherein said polypeptide is expressed *in vivo* in muscle cells for at least 90 days after administration of said composition and is distributed throughout the muscle mass;

and (ii) a pharmaceutically acceptable carrier.

16. (canceled)

17. (previously presented) The composition according to claim 15, wherein said polynucleotide sequence encodes a polypeptide having thrombolytic properties.

18. (previously presented) The composition according to claim 15, wherein said polynucleotide sequence encodes a polypeptide which is all or part of a dystrophin gene product.

19. (currently amended) The ~~method~~ composition according to claim 15, wherein said polynucleotide sequence encodes a polypeptide which is a β -galactosidase gene product.

20-21. (canceled)